Bristol Myers Squibb Co (BMY) stock
BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 14/3030% below fair value
$59.56−1.79 (-2.92%)
Close on Nov 18, 2026Market cap $121.75BP/E 13.2Yield 4.18%
Bristol Myers Squibb r&d expenses
Research and development expenses are spending on new products and technology.
Bristol Myers Squibb's R&D Expenses for the twelve months ending Sep 30, 2026 was $10.56B, up 0.0% year over year. For fiscal 2025 it was $9.95B, down 10.8% from the year before. Over ten years it grew 5.3% a year on average. The highest annual figure on record is $11.16B in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.95B | -10.8% |
| FY2024 | Dec 31, 2024 | $11.16B | +20.0% |
| FY2023 | Dec 31, 2023 | $9.30B | -2.2% |
| FY2022 | Dec 31, 2022 | $9.51B | -6.7% |
| FY2021 | Dec 31, 2021 | $10.20B | +1.5% |
| FY2020 | Dec 31, 2020 | $10.05B | +63.4% |
| FY2019 | Dec 31, 2019 | $6.15B | -2.9% |
| FY2018 | Dec 31, 2018 | $6.33B | -2.1% |
| FY2017 | Dec 31, 2017 | $6.47B | +29.1% |
| FY2016 | Dec 31, 2016 | $5.01B | -15.3% |
| FY2015 | Dec 31, 2015 | $5.92B | +30.6% |
| FY2014 | Dec 31, 2014 | $4.53B | +21.5% |
| FY2013 | Dec 31, 2013 | $3.73B | -4.4% |
| FY2012 | Dec 31, 2012 | $3.90B | +1.7% |
| FY2011 | Dec 31, 2011 | $3.84B | +7.7% |
| FY2010 | Dec 31, 2010 | $3.57B | -2.2% |
| FY2009 | Dec 31, 2009 | $3.65B | +3.8% |
| FY2008 | Dec 31, 2008 | $3.51B | +11.1% |
| FY2007 | Dec 31, 2007 | $3.16B | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.37B | -6.4% |
| Q2 FY2026 | Jun 30, 2026 | $2.96B | +14.7% |
| Q1 FY2026 | Mar 31, 2026 | $2.65B | +17.4% |
| Q4 FY2025 | Dec 31, 2025 | $2.59B | -19.0% |
| Q3 FY2025 | Sep 30, 2025 | $2.53B | +6.5% |
| Q2 FY2025 | Jun 30, 2025 | $2.58B | -11.0% |
| Q1 FY2025 | Mar 31, 2025 | $2.26B | -16.3% |
| Q4 FY2024 | Dec 31, 2024 | $3.19B | +28.8% |
| Q3 FY2024 | Sep 30, 2024 | $2.37B | +5.9% |
| Q2 FY2024 | Jun 30, 2024 | $2.90B | +28.4% |
| Q1 FY2024 | Mar 31, 2024 | $2.70B | +16.1% |
| Q4 FY2023 | Dec 31, 2023 | $2.48B | -1.3% |
| Q3 FY2023 | Sep 30, 2023 | $2.24B | -7.3% |
| Q2 FY2023 | Jun 30, 2023 | $2.26B | -2.7% |
| Q1 FY2023 | Mar 31, 2023 | $2.32B | +2.7% |
| Q4 FY2022 | Dec 31, 2022 | $2.51B | -0.3% |
| Q3 FY2022 | Sep 30, 2022 | $2.42B | -18.9% |
| Q2 FY2022 | Jun 30, 2022 | $2.32B | -6.3% |
| Q1 FY2022 | Mar 31, 2022 | $2.26B | +1.8% |
| Q4 FY2021 | Dec 31, 2021 | $2.52B | -5.2% |
| Q3 FY2021 | Sep 30, 2021 | $2.98B | +19.2% |
| Q2 FY2021 | Jun 30, 2021 | $2.48B | -1.7% |
| Q1 FY2021 | Mar 31, 2021 | $2.22B | -6.5% |
| Q4 FY2020 | Dec 31, 2020 | $2.66B | +26.6% |
| Q3 FY2020 | Sep 30, 2020 | $2.50B | +81.3% |
| Q2 FY2020 | Jun 30, 2020 | $2.52B | +90.3% |
| Q1 FY2020 | Mar 31, 2020 | $2.37B | +76.0% |
| Q4 FY2019 | Dec 31, 2019 | $2.10B | +53.4% |
| Q3 FY2019 | Sep 30, 2019 | $1.38B | +7.7% |
| Q2 FY2019 | Jun 30, 2019 | $1.33B | -45.6% |
| Q1 FY2019 | Mar 31, 2019 | $1.35B | +7.8% |
| Q4 FY2018 | Dec 31, 2018 | $1.37B | -29.0% |
| Q3 FY2018 | Sep 30, 2018 | $1.28B | -18.0% |
| Q2 FY2018 | Jun 30, 2018 | $2.44B | +45.0% |
| Q1 FY2018 | Mar 31, 2018 | $1.25B | -4.1% |
| Q4 FY2017 | Dec 31, 2017 | $1.93B | +30.8% |
| Q3 FY2017 | Sep 30, 2017 | $1.56B | – |
| Q2 FY2017 | Jun 30, 2017 | $1.68B | – |
| Q1 FY2017 | Mar 31, 2017 | $1.30B | – |
| Q4 FY2016 | Dec 31, 2016 | $1.47B | – |
See a number that looks wrong?